Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

被引：86
|
作者：
Saltarella, Ilaria [1 ]
Desantis, Vanessa [1 ]
Melaccio, Assunta [1 ]
Solimando, Antonio Giovanni [1 ]
Lamanuzzi, Aurelia [1 ]
Ria, Roberto [1 ]
Storlazzi, Clelia Tiziana [2 ]
Mariggio, Maria Addolorata [3 ]
Vacca, Angelo [1 ]
Frassanito, Maria Antonia [3 ]
机构：
[1] Univ Bari Aldo Moro, Unit Internal Med & Clin Oncol, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy
[2] Univ Bari Aldo Moro, Dept Biol, I-70125 Bari, Italy
[3] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Unit Gen Pathol, I-70124 Bari, Italy
来源：
CELLS | 2020年 / 9卷 / 01期
关键词：
multiple myeloma; CD38; antigen; daratumumab; drug resistance; MONOCLONAL-ANTIBODY THERAPY; DRUG-RESISTANCE; CD38; EXPRESSION; COMPLEMENT REGULATORS; MEDIATED PHAGOCYTOSIS; ANTITUMOR-ACTIVITY; CELLS; BONE; GAMMA; BORTEZOMIB;
D O I：
10.3390/cells9010167
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients.
引用
收藏
页数：14
相关论文
共 50 条
  • [31] Could anti-CD38 (daratumumab) be used in the management of severe allergic diseases?
    Blankestijn, M. A.
    Van de Donk, N. W.
    Sasser, K.
    Knulst, A. C.
    Otten, H. G.
    ALLERGY, 2017, 72 : 322 - 322
  • [32] Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication
    Tai, Yu-Tzu
    de Weers, Michel
    Li, Xian-Feng
    Song, Weihua
    Nahar, Sabikun
    Bakker, Joost M.
    Vink, Tom
    Jacobs, Danielle
    Oomen, Lukas
    Bleeker, Wim K.
    Munshi, Nikhil C.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Richardson, Paul
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 252 - 252
  • [33] Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients
    De Acha, Olivia Perez
    Idler, Beau M.
    Walker, Zachary J.
    Forsberg, Peter A.
    Mark, Tomer M.
    Sherbenou, Daniel W.
    BLOOD, 2020, 136
  • [34] Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab
    Nijhof, Inger S.
    Lokhorst, Henk M.
    van Kessel, Berris
    Groen, Richard W. J.
    Martens, Anton C.
    Doshi, Parul
    Klein, Saskia K.
    Mutis, Tuna
    Sasser, Kate
    van de Donk, Niels W. C. J.
    BLOOD, 2014, 124 (21)
  • [35] Myeloma Patients Receiving Daratumumab (Anti-CD38) Can Appear to Have an Antibody with Lutheran-related Specificity
    Aye, T.
    Arndt, P. A.
    Leger, R. M.
    Do, J.
    Rodberg, K.
    Aldridge, L.
    Wang, S.
    TRANSFUSION, 2015, 55 : 28A - 28A
  • [36] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
    Lokhorst, H. M.
    Plesner, T.
    Laubach, J. P.
    Nahi, H.
    Gimsing, P.
    Hansson, M.
    Minnema, M. C.
    Lassen, U.
    Krejcik, J.
    Palumbo, A.
    van de Donk, N. W. C. J.
    Ahmadi, T.
    Khan, I.
    Uhlar, C. M.
    Wang, J.
    Sasser, A. K.
    Losic, N.
    Lisby, S.
    Basse, L.
    Brun, N.
    Richardson, P. G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13): : 1207 - 1219
  • [37] EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
    Djamila Chemlal
    Emmanuel Varlet
    Amelie Machura
    Sara Ovejero
    Guilhem Requirand
    Nicolas Robert
    Guillaume Cartron
    Elina Alaterre
    Caroline Bret
    Laure Vincent
    Charles Herbaux
    Giacomo Cavalli
    Angélique Bruyer
    Hugues De Boussac
    Jerome Moreaux
    Leukemia, 2023, 37 : 1925 - 1928
  • [38] SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma
    An, Gang
    Jiang, Hua
    Acharya, Chirag
    Zhong, Mike Y.
    Cai, Ti
    Yang, Guang
    Song, Zhili
    Theilhaber, Joachim
    Adrian, Francisco
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    BLOOD, 2014, 124 (21)
  • [39] Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab
    Yashar, David
    Regidor, Bernard Sean S.
    Jew, Scott Kristian
    Bujarski, Sean
    Goldwater, Marissa-Skye
    Swift, Regina
    Schwartz, Gary Edward
    Eshaghian, Shahrooz
    Vescio, Robert
    Berenson, James R.
    BLOOD, 2021, 138 : 3785 - +
  • [40] Analyzing Risk of Infection with Anti-CD38 Monoclonal Antibody Therapy for Patients with Multiple Myeloma
    Hong, Augustine
    Eduafo, Augusta
    Schmikla, Hannah
    Brown, George
    Ravi, Gayathri
    de Lima, Marcos
    Malek, Ehsan
    BLOOD, 2020, 136
12345